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Data collection 
Principal investigators were invited to join this collaborative group if they had published or unpublished 
studies on prostate cancer risk and endogenous sex hormone concentrations and/or nutritional biomarkers 
from blood samples collected from men prior to diagnosis of prostate cancer and male controls. Studies were 
identified by literature searches of computerised bibliographic systems, including PubMed, Web of Science, 
Cochrane Library, and CancerLit, and through discussions with colleagues, as described previously1, 2. 
Collaborators provided data on baseline IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations and 
a range of anthropometric (including height, weight, waist circumference and waist-to-hip ratio (WHR)), 
behavioural (smoking and alcohol), and sociodemographic factors (racial/ethnic group, education status), 
generally collected at the same time as blood collection (Supplementary Tables 1, 2a and 2b). The data from 
each study were collected and incorporated into a central database. 
Men were considered eligible for this analysis if they had measures of at least one of circulating IGF-I, IGF-
II, IGFBP-1, IGFBP-2, or IGFBP-3 concentrations, had not been diagnosed with prostate cancer by the time 
of censoring, and had recorded age, height and weight at the time blood collection. Overall, these exclusion 
criteria resulted in 16,024 men (out of 17,838; Supplementary Figure 1) from the following studies: Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC)3, Baltimore Longitudinal Study of Aging 
(BLSA)4, British United Provident Association Study (BUPA)5, Child Health and Development Studies 
(CHDS)6, Cardiovascular Health Study (CHS)7, European Prospective Investigation into Cancer and 
Nutrition (EPIC)8, 9, Health In Men Study (HIMS)10, 11,  Health Professionals Follow-up Study (HPFS)12-14, 
Japan Collaborative Cohort Study (JACC)15, Kaiser Permanente Medical Care Program (KPMCP)16, 
Melbourne Collaborative Cohort Study (MCCS)17, Multiethnic Cohort (MEC)18, Northern Sweden Health 
and Disease Cohort (NSHDC)19, 20, Prostate Cancer Prevention Trial (PCPT)21, Physicians’ Health Study 
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(PHS)22-24, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)25, Prostate Testing for 
Cancer and Treatment (ProtecT) feasibility study26 and main study27, SUpplémentation en VItamines et 
Minéraux AntioXydants (SU.VI.Max)28, by dataset closure on January 1st, 2018 
The characteristics of these studies in the collaborative analyses are found in their original publications and 
are summarised in Supplementary Table 1. All studies are either of a prospective cohort design4-13, 15-18 or 
prospective observational studies within a randomised trial3, 19-29. This analysis used secondary data, 
therefore ethical approval for this analysis was not necessary; however, each study individually obtained 
ethical approval and further details of participant consent and study design can be found in the original 
publications3-13, 15-29.  
Data Processing  
IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations were logarithmically transformed to 
approximate normal distributions. The analyses examined associations with age (22-49 [mean age=42.6], 
50-54, 55-59, 60-64, 65-69, 70-74, 75+ years), body mass index (BMI [<20.0, 20.0-22.4, 22.5-24.9, 25.0-
27.4, 27.5-29.9, 30.0-32.4, 32.5-34.9, 35.0-37.4, 37.5+ kg/m2]), height (<160.0, 160.0-164.9, 165.0-169.9, 
170.0-174.9, 175.0-179.9, 180.0-184.9, 185.0-189.9, 190.0+ cm), smoking status (never, former, current: 
<15, 15-29, 30+ cigarettes per day), alcohol consumption (none, 1-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-
69, 70+ g ethanol per day), ethnic/racial group (non-Hispanic white, African American/Caribbean, 
Hispanic/Latino, East Asian, and other), waist circumference (<90.0, 90.0-94.9, 95.0-99.9, 100.0-104.9, 
105.0+ cm), WHR (<0.900, 0.900-0.932, 0.933-0.966, 0.967-0.999, 1.00+), marital status (currently 
married/cohabiting, not currently married/cohabiting), and family history of prostate cancer (no, yes: defined 
as a father and/or brother diagnosed with prostate cancer) with circulating IGF and IGFBP concentrations. 
Categories of the exposure variables investigated were defined a priori based on sample size and the data 
distribution 
Statistical Analysis 
Partial correlations between the IGFs and IGFBPs were calculated using study-specific standardised values: 
(xjk-mj)/sj, where mj and sj denote the mean and standard deviation of the log-transformed IGF concentrations 
in study j and xjk is an observation from that study, enabling comparison across studies. These standardised 
correlation coefficients were adjusted for age at blood collection, BMI and height (included as categorical 
variables, described above).  
Geometric mean concentrations of IGFs and IGFBPs were calculated using predicted values from analysis 
of variance models scaled to the overall geometric mean concentration and adjusted for study, age at blood 
collection, BMI, and height (with the exception of when we analysed the associations of age, BMI and 
height with IGF and IGFBP concentrations, where the exposure variable was not included as an adjustment 
 3 
 
covariate). Adjusted geometric mean concentrations in relation to waist circumference and WHR were also 
repeated with and without adjustment for BMI. Analyses of smoking and alcohol consumption were 
mutually adjusted for each other. To enable robust adjustment for study, each study had to contain 
observations in a minimum of two categories for each primary exposure to be included in the respective 
exposure analysis. To investigate the relationship of IGF and IGFBP concentrations with ethnicity/race, 
studies were limited to the five (all USA-based) studies that had sufficient representation from men across 
multiple ethnic/racial groups (CHDS, CHS, MEC, PCPT, PHS).  
Tests for heterogeneity 
Heterogeneity of means by category of each characteristic was tested using the F test. Where appropriate, a 
test for trend was calculated using the analysis of variance test, with the categorical variables entered as 
linear values scored consecutively as 1, 2, 3 etc. Owing to the highly skewed distribution of alcohol 
consumption, the test for trend was calculated based on median values within each category excluding non-
drinkers. To test for trend by smoking status, never and former smokers were combined and coded as 0; 
light, medium and heavy smokers were coded as 1, 2 and 3, respectively as current smoking status may be 
more likely to determine circulating IGF and IGFBP concentrations than previous smoking history. In a 
secondary analysis the test for trend was calculated for current smokers only. 
Heterogeneity between studies was tested using a study-by-factor interaction term (fitted separately) in the 
analysis of variance, and assessed using the F test. Circulating IGFBP-1 and IGFBP-2 concentrations are 
known to be affected by food intake30, 31; as fasting status was not recorded for 58% of participants, 
therefore this variable was not included as a covariate in the analyses, but heterogeneity between exposure 
factors and overnight fasting status for these two binding proteins was assessed using the likelihood ratio 
test. 
Sensitivity analysis 
The analyses were conducted after restricting the dataset to: i) white men only (n=11,611), ii) studies which 
used enzyme-linked immunosorbent assays (ELISA), iii) men with IGF and IGFBP concentrations that were 
within the range of [lower quartile – 3*interquartile range, upper quartile + 3*interquartile range] within 
each study in order to examine the effect of outliers (n=147). The primary analysis was also repeated after 
further adjustment for smoking and alcohol. 
Statistical software 
All statistical tests were two-sided, and due to the multiple tests conducted the statistical significance 
threshold was p<0.01. Data analysis was carried out using Stata Statistical Software release 14.1 (Stata 
Corp., College Station, TX, USA).  
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Supplementary Tables and Figures  
Supplementary Table 1: Participant characteristics by study 
 
* ProtecT feasibility study 
† Excludes missing data  
a Excludes studies where data were not collected 
‡ Not published 
Abbreviations: ATBC=The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA= The Baltimore Longitudinal Study of Aging; BUPA= British United Provident Association Study; CHDS=Child Health and Development 
Studies; CHS=Cardiovascular Health Study; EPIC= European Prospective Investigation into Cancer and Nutrition; HIMS= Health In Men Study; HPFS= Health Professionals Follow-up Study; JACC= Japan Collaborative Cohort Study for 
Evaluation of Cancer; KPMCP= Kaiser Permanente Medical Care Program; MCCS=Melbourne Collaborative Cohort Study; MEC= Multiethnic Cohort Study of Diet and Cancer; NSHDC=Northern Sweden Health and Disease Cohort; 
Study, country N (% of total) 
Year of 
blood 
collection 
Mean age, 
years (SD) 
Age range, 
years 
Mean height, 
cm (SD) 
Mean BMI, 
kg/m2 (SD) 
% Current 
drinkers (median 
daily alcohol 
consumption, g 
ethanol) 
% Current smokers 
(median number of 
daily cigarettes) 
% White 
ethnic group 
% Married/ 
cohabiting at 
blood 
collection 
% University 
degree 
% Family 
history of 
prostate cancer 
ATBC3, Finland 311 (1.9) 1985-1988 58.5 (4.5) 52-70 173.5 (5.9) 26.5 (3.9) 82.2 (10) 100 (20) 100 81.4 5.5 4.2 
BLSA4, USA 110 (0.7) 1969-1993 64.7 (9.4) 43-83 175.0 (6.7) 26.5 (3.7) - 7.3 97.3 83.3 58.2 - 
BUPA5, UK 423 (2.6) 1975-1982 54.5 (6.2) 36-64 175.6 (7.0) 25.4 (2.9) 98.1 (15)  19.1 (20) - - - - 
CHDS6, USA 434 (2.7) 1959-1966 33.9 (6.9) 22-50 178.6 (6.7) 24.6 (2.7) 76.8 (5) 52.0 (20) 62.4 99.8 33.1 - 
CHS7, USA 174 (1.1) 1989-1993 72.4 (4.4) 65-89 173.5 (6.6) 26.7 (4.1) - 13.8 75.7 83.3 14.5 - 
EPIC phase I8, Europe 636 (4.0) 1992-1999 60.9 (6.2) 43-76 172.6 (7.0) 27.0 (3.6) 87.2 (13) 27.9 (15) 100 89.3 23.0 - 
EPIC phase II8, 9, Europe 1,193 (7.4) 1992-1999 58.7 (6.1) 39-77 174.3 (6.8) 26.7 (3.6) 90.5 (13) 25.9 (15) 100 88.5 24.1 - 
EPIC phase III/IV‡, Europe 1,787 (11.2) 1992-1999 56.1 (7.2) 36-78 172.5 (7.2) 26.9 (3.4) 88.8 (14) 25.3 (16) 100 88.4 23.1 - 
HIMS10, 11, Australia 1,279 (8.0) 2001-2004 76.3 (3.6) 71-87 171.7 (6.9) 26.5 (3.7) 65.9 (7) 4.8 100 86.3 21.4 - 
HPFS I12, 13, USA 682 (4.3) 1993-1995 65.1 (7.4) 46-80 178.1 (6.4) 26.0 (3.5) 73.5 (6) 3.9 (20) 99.4 93.0 100 10.3 
HPFS II12-14, USA 629 (3.9) 1993-1995 62.0 (7.8) 46-80 177.5 (6.7) 26.1 (3.6) 71.5 (6) 3.0 92.4 93.0 100 10.8 
JACC15, Japan 94 (0.6) 1988-1991 68.1 (5.6) 58-83 159.4 (6.9) 22.4 (2.7) 52.1 (2) 37.0 (20) 0.0 93.4 2.7 - 
KPMCP16, USA 212 (1.3) 1964-1970 71.8 (4.5) 60-85 169.9 (6.7) 25.8 (3.1) 69.7 (10) 17.9 (30) 98.6 82.7 5.4 - 
MCCS17, Australia 1,047 (6.5) 1990-1994 58.3 (7.2) 40-72 172.1 (7.3) 27.2 (3.7) 78.3 (13) 13.2 (20) 100 81.0 22.2 - 
MEC18, USA 772 (4.8) 1994-2004 68.5 (7.1) 49-84 173.9 (7.7) 26.9 (4.1) 90.5 (9) 11.7 (15) 14.5 79.2 31.9 8.3 
NSHDC19, 20, Sweden 557 (3.5) 1987-2000 57.9 (4.3) 40-72 175.4 (5.9) 26.6 (3.7) 100 (4) 20.8 100 80.0 12.3 - 
PCPT21, USA and Canada 1,022 (6.4) 1993-1996 63.3 (5.5) 55-83 177.5 (7.0) 27.6 (4.0) 69.0 (3) 7.6 (20) 84.0 87.7 37.0 20.7 
PHS22-24, USA 757 (4.7) 1982-1983 58.4 (8.0) 39-84 178.1 (6.8) 24.7 (2.5) 83.6 (5) 8.9 (20) 94.2 - 100 15.4 
PLCO25, USA 858 (5.4) 1994-2000 64.8 (4.8) 54-75 177.9 (6.5) 27.4 (3.9) 70.0 (4) 9.1 (20) 100 86.9 42.4 6.1 
ProtecT feas*26, UK 568 (3.5) 1999-2001 61.5 (5.0) 50-70 175.3 (6.5) 26.6 (3.6) 83.5 (17) 10.9 - - - 4.1 
ProtecT main27, UK 1,770 (11.0) 2002-2009 61.9 (5.0) 45-70 176.1 (6.5) 26.9 (3.7) 84.6 (17) 13.6 - - - 5.6 
SU.VI.MAX28 , France 709 (4.4) 1994-1995 54.3 (4.5) 42-61 173.4 (6.3) 25.5 (3.0) 82.6 (28) 13.0 - 87.7 30.8 4.4 
Overall† 16,024 1959-2009 61.2 (9.5) 22-89 174.7 (7.3) 26.6 (3.7) 80.6 (10) 17.0 (20) 90.4 87.0 38.1 8.8 
% Missing dataa - - - - - - 7.8 1.3 19.9 31.4 19.7 56.8 
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PCPT= Prostate Cancer Prevention Trial; PHS=Physicians' Health Study; PLCO= The Prostate, Lung, Colorectal and Ovarian; ProtecT= Prostate Testing for Cancer and Treatment; SU. VI MAX= SUpplémentation en VItamines et 
Minéraux AntioXydants; UK=United Kingdom; USA= United States of America.  
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Supplementary Table 2a: Assay methods and geometric mean analyte concentrations in IGFs 
* ProtecT feasibility study 
†Intra-assay  
a Inter-assay  
‡Intra-and inter-assay range 
¶ Not specified 
b Separate study assay populations 
** Not published 
Abbreviations: ATBC=The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA= The Baltimore Longitudinal Study of Aging; BUPA= British United Provident Association Study; CHDS= Child Health and Development 
Studies; CHS=Cardiovascular Health Study; CLIA= chemiluminescent immunometric assay; CV=coefficient of variation; E= extraction step; ECIA= electrochemiluminescence immunoassay; EDTA= ethylenediaminetetraacetic acid; 
ELISA= enzyme-linked immunosorbent assay; EPIC= European Prospective Investigation into Cancer and Nutrition; HIMS= Health In Men Study; HPFS= Health Professionals Follow-Up Study; ICC= intraclass correlations; IGF= Insulin-
like growth factor; IGFBP= Insulin-like growth factor; IRMA= Immunoradiometric assay; JACC= Japan Collaborative Cohort Study for Evaluation of Cancer; KPMCP= Kaiser Permanente Medical Care Program; MCCS=Melbourne 
Collaborative Cohort Study; MEC= Multiethnic Cohort Study of Diet and Cancer; NSHDC=Northern Sweden Health and Disease Cohort; PCPT= Prostate Cancer Prevention Trial; PHS=Physicians' Health Study; PLCO= The Prostate, 
Lung, Colorectal and Ovarian; ProtecT= Prostate Testing for Cancer and Treatment; RIA= radioimmuoassay; SU.VI.MAX= SUpplémentation en VItamines et Minéraux AntioXydants 
  IGF-I (nmol/L)  IGF-II (nmol/L) 
Study, publication year(s) Sample Method 
Geometric mean 
(95% CI) 
CV %  Method Geometric mean (95% CI) CV % 
ATBC, 2003 Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 17.7 (17.0-18.4) 6.6‡  - - - 
BLSA, 2000 Serum E RIA (Endocrine Sciences, Calabasas Hills, California) 17.8 (16.6-19.0) 4.6-20‡  E RIA (Endocrine Sciences, Calabasas Hills, California) 40.8 (38.7-43.1) 4.9-30‡ 
BUPA, 2006 Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 15.0 (14.5-15.6) N/A  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 89.7 (87.3-92.2) - 
CHDS, 1988 - Not published 30.2 (29.2-31.2)   - - - 
CHS, 2005 EDTA 
plasma 
IRMA (Diagnostic Systems Laboratories, Webster, Texas) 19.2 (18.2-20.3) 3.0-12.3‡  - - - 
EPIC phase I, 2007b Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas, phase 1 
and phase 2 excluding Swedish samples) 
IDS-iSYS (Immuno-diagnostic Systems Ltd, Swedish samples for 
phase 2) 
21.2 (20.6-21.8) 3.0-13.7‡  - - - 
EPIC phase II, 2012b Serum 19.1 (18.7-19.5) 3.2-4.4‡  Not published 111.6 (109.4-113.8)  
EPIC phase III/IV** b Serum - - -  ELISA (Ansh Labs, Webster, Texas) 59.3 (58.6-60.9) 2.5-3.6a 
HIMS, 2010 Plasma ELISA  (Diagnostic Systems Laboratories, Gladesville, NSW, 
Australia) 
16.8 (16.5-17.2) 8.6-12.2 a  - - - 
HPFS I, 2005, 2011b Plasma ELISA (Diagnostic Systems Laboratories, Webster, Texas) 22.2 (21.6-22.8) <10 (batch 1998 
to 2000, 
CV=13.1)† 
 - - - 
HPFS II, 2011, 2015b Plasma ELISA (Diagnostic Systems Laboratories, Webster, Texas) 27.2 (26.4-27.9)  - - - 
JACC, 2010 Serum IRMA (Daiichi Radioisotope Lab, Tokyo, Japan) 13.0 (12.1-14.0) 2.1-3.5†  IRMA (Daiichi Radioisotope Lab, Tokyo, Japan) 68.5 (64.9-72.8) 2.7-4.4† 
KPMCP, 1998 Serum E RIA (Nichols Institute Diagnostics, San Clemente, California) 20.7 (19.7-21.7) N/A  - - - 
MCCS, 2006 Plasma ELISA (Diagnostic Systems Laboratories, Webster, Texas) 21.8 (21.4-22.3) 11.1a  - - - 
MEC, 2010 Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 22.9 (22.4-23.5) 2.1†  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 114.4 (112.0-117.0) 1.8† 
NSHDC, 2000, 2004 Plasma E IRMA (Immunotech, Marseille, France) 25.3 (24.6-26.1) 8.6-13.8‡  - - - 
PCPT, 2013 Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 26.1 (25.5-26.7) 5.3-7.1†  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 223.8 (219.9-227.7) 4.2-5.0† 
PHS, 1998, 2002, 2010 Plasma ELISA (Diagnostic Systems Laboratories, Webster, Texas) 22.7 (22.1-23.3) 4.9-6.5†  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 66.5 (63.5-69.7) N/A 
PLCO, 2007 Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 24.9 (24.3-25.5) 9‡  - - - 
ProtecT feas, 2004* Serum ELISA (Diagnostic Systems Laboratories, Webster, Texas) 16.1 (15.7-16.6) 3-15‡  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 54.1 (52.9-55.4) 5-26‡ 
ProtecT main, 2012 Serum RIA (Professor Holly, in house assay) 20.5 (20.2-20.9) ICC 0.66-0.86  RIA (Professor Holly, in house assay) 96.9 (95.6-98.2) ICC 0.84- 0.91 
SU.VI.MAX, 2005  Plasma CLIA  (Diagnostic Products, Los Angeles, California) 19.0 (18.5-19.4) 5.3¶  IRMA (Immunotech, Marseille, France) 140.6 (138.7-142.7) 6.8 ¶  
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Supplementary Table 2b: Assay methods and geometric mean analyte concentrations in IGFBPs 
 
* ProtecT feasibility study 
†Intra-assay  
a Inter-assay  
‡Intra-and inter-assay range 
¶ Not specified 
b Separate study assay populations 
** Not published 
Abbreviations: ATBC=The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA= The Baltimore Longitudinal Study of Aging; BUPA= British United Provident Association Study; CHDS= Child Health and Development 
Studies; CHS=Cardiovascular Health Study; CLIA= chemiluminescent immunometric assay; CV=coefficient of variation; E= extraction step; ECIA= electrochemiluminescence immunoassay; EDTA= ethylenediaminetetraacetic acid; 
ELISA= enzyme-linked immunosorbent assay; EPIC= European Prospective Investigation into Cancer and Nutrition; HIMS= Health In Men Study; HPFS= Health Professionals Follow-Up Study; ICC= intraclass correlations; IGF= Insulin-
like growth factor; IGFBP= Insulin-like growth factor; IRMA= Immunoradiometric assay; JACC= Japan Collaborative Cohort Study for Evaluation of Cancer; KPMCP= Kaiser Permanente Medical Care Program; MCCS=Melbourne 
Collaborative Cohort Study; MEC= Multiethnic Cohort Study of Diet and Cancer; NSHDC=Northern Sweden Health and Disease Cohort; PCPT= Prostate Cancer Prevention Trial; PHS=Physicians' Health Study; PLCO= The Prostate, 
Lung, Colorectal and Ovarian; ProtecT= Prostate Testing for Cancer and Treatment; RIA= radioimmuoassay; SU.VI.MAX= SUpplémentation en VItamines et Minéraux AntioXydants 
 
 
  IGFBP-1 (nmol/L)  IGFBP-2 (nmol/L)  IGFBP-3 (nmol/L) 
Study, publication 
year(s) 
Sample 
Method 
Geometric mean 
(95% CI) 
CV %  Method 
Geometric mean    
(95% CI) 
CV %  Method Geometric mean  95% CI) CV % 
ATBC, 2003 Serum - - -  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 79.0 (76.7-81.3) 7.30† 
BLSA, 2000 Serum - - -  - - -  NE RIA (Endocrine Sciences, Calabasas Hills, California) 94.8 (90.1-99.6) 5.1-17‡ 
BUPA, 2006 Serum - - -  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 95.2 (92.8-97.6) - 
CHDS, 1988 - - - -  - - -  - - - 
CHS, 2005 EDTA 
plasma 
- - -  - - -  IRMA (Diagnostic Systems Laboratories, Webster, Texas) 108.2 (104-112.6) 2.1-7.1‡ 
EPIC phase I, 2007 Serum Not published 0.24 (0.22-0.26)   - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 128.8 (126.2-131.5) 5.30-9.40‡ 
EPIC phase II, 2012**b Serum - - -  Not published 11.4 (10.9-11.9)   - - - 
EPIC phase III/IV** b Serum ELISA (Alpco, Salem, New 
Hampshire) 
0.05 (0.05-0.05) 2.2-3.9a  ELISA (Ansh Labs, Webster, Texas) 2.81 (2.73-2.90) 2.0-4.4a  - - - 
HIMS, 2010 Plasma ELISA (Diagnostic Systems 
Laboratories, Gladesville, NSW, 
Australia) 
0.78 (0.74-0.83) 5.2-8.6 a  - - -  ELISA (Diagnostic Systems Laboratories, Gladesville, 
NSW, Australia) 
128.7 (126.8-130.6) 4.4-16.8a 
HPFS I, 2005b Plasma - - -  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 112.1 (109.8-114.3) <10† 
HPFS II 2011, 2015b Plasma ELISA (Diagnostic Systems 
Laboratories, Webster, Texas) 
0.65 (0.59-0.71) 2.2-17.2†  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 126.7 (124.1-129.4) <10† 
JACC, 2010 Serum - - -  - - -  IRMA (Daiichi Radioisotope Lab, Tokyo, Japan) 90.6 (85.8-95.6) 3.1-4.2† 
KPMCP, 1998 Serum - - -  - - -  - - - 
MCCS, 2006 Plasma - - -  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 103.6 (101.9-105.2) 9.5¶  
MEC, 2010 Serum ELISA (Diagnostic Systems 
Laboratories, Webster, Texas) 
0.74 (0.68-0.80) 2.2†  - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 132.1 (129.7-134.6) 2.50† 
NSHDC, 2000, 2004 Plasma IRMA (Diagnostic Systems 
Laboratories, Webster, Texas) 
1.30 (1.44-1.48) 2.9†  RIA (Diagnostic Systems 
Laboratories, Webster, Texas) 
16.4 (15.3-17.7) 2.50†  IRMA (Immunotech, Marseille, France) 80.2 (78.4-81.9) 3.6-6.9‡ 
PCPT, 2013 Serum - - -  ELISA (Diagnostic Systems 
Laboratories, Webster, Texas) 
14.0 (13.5-14.5) 5.5-8.9‡  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 136.6 (134.4-138.9) 4.2-4.8† 
PHS, 1998, 2002, 2010 Plasma Not published 0.16 (0.15-0.18)   - - -  ELISA (Diagnostic Systems Laboratories, Webster, Texas) 107.8 (105.8-109.8) 7-9† 
PLCO, 2007 Serum - - -  - - -  ELISA 155.2 (152.4-158.0) 9† 
ProtecT feas, 2004* Serum - - -  RIA (Diagnostic Systems 
Laboratories, Webster, Texas) 
16.5 (15.6-17.3) 5-14‡  RIA in-house 107.4 (105.0-109.8) 4-14‡ 
ProtecT main, 2012 Serum - - -  ELISA (Diagnostic Systems 
Laboratories) 
18.4 (17.9-18.9) ICC 0.81-0.95‡  RIA (Professor Holly, in house assay) 149.5 (147.6-151.4) ICC 0.71- 0.88 
SU.VI.MAX, 2005 Plasma - - -  RIA (Diagnostic Systems 
Laboratories, Webster, Texas) 
6.6 (6.1-7.1) 8.6%¶  CLIA (Diagnostic Products, Los Angeles, California) 143.0 (139.9-146.2) 6.3¶ 
 8 
 
 
Supplementary Table 3: Partial correlation coefficients 
between log-transformed IGFs and IGFBPs  
 
 
 
 
 
 
Measurements are standardised by study and adjusted for age, BMI and height.  
Number of observations ranged from 12,012 (IGF-I and IGFBP-3) to 2,873 (IGFBP-1 and IGFBP-2) 
*P<0.01 
Abbreviations: BMI= Body mass index; IGF= Insulin-like growth factor; IGFBP= Insulin-like growth factor-binding protein
Analyte IGF-I IGF-II IGFBP-1 IGFBP-2 IGFBP-3 
IGF-I  1     
IGF-II  0.41*  1    
IGFBP-1 -0.15* -0.11*  1   
IGFBP-2 -0.09* -0.20*  0.42*  1  
IGFBP-3  0.58*  0.65* -0.12* -0.19*  1 
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Supplementary Figure 1: Participant selection chart
Controls with 
hormone data 
n=17,838  
Duplicate controls 
excluded  
n=24 
Unique controls 
n=17,814 
Final sample 
n=16,024 
Men with missing 
data on age, 
height and/or 
weight 
n=1,790 
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Supplementary Figure 2: Relative geometric mean concentrations* of IGFs and IGFBPs in males by waist circumference 
P for heterogeneity is the heterogeneity of means between categories, tested using the F test. P for trend was calculated using the analysis of variance test, with categorical variables entered as 
linear values scored consecutively.    
*relative to < 90-94 cm  
#significant heterogeneity by study P<0.01  
0.5 1 1.5 2
Relative geometric mean* (95% CI)
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N
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869
747
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664
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1086
982
1036
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982
692
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842
1310
1165
1246
936
1327
Geometric mean 
concentration 
(95% CI) 
21.0 (21.7-21.4)
21.4 (21.0-21.8)
22.0 (21.6-22.4)
21.5 (21.1-22.0)
20.3 (20.0-20.7)
93 (92-95)
95 (93-97)
100 (98-101)
98 (96-100)
97 (95-99)
0.32 (0.31-0.34)
0.23 (0.22-0.24)
0.19 (0.18-0.20)
0.17 (0.16-0.18)
0.13 (0.12-0.14)
9.23 (8.85-9.62)
6.84 (6.55-7.14)
5.67 (5.46-5.90)
5.16 (4.93-5.39)
4.28 (4.12-4.45)
118 (116-120)
120 (118-122)
122 (120-124)
120 (118-122)
118 (116-120)
P-het 
(trend)
<0.0001
(0.0319)
<0.0001 #
(0.0005)
<0.0001 #
(<0.0001)
<0.0001 
(<0.0001)
0.0049
(0.9819)
Geometric mean 
concentration (95% 
CI) further adjusted 
for BMI
21.2 (20.7-21.7)
21.2 (20.8-21.6)
21.7 (21.3-22.1)
21.4 (20.9-21.9)
20.7 (20.2-21.3)
94 (92-96)
94 (92-97)
99 (97-101)
98 (96-100)
98 (95-100)
0.25 (0.23-0.27)
0.21 (0.20-0.22)
0.19 (0.18-0.21)
0.19 (0.18-0.21)
0.17 (0.16-0.18)
7.17 (6.79-7.58)
6.18 (5.91-6.48)
5.68 (5.46-5.91)
5.63 (5.37-5.89)
5.34 (5.07-5.62)
118 (116-120)
119 (117-121)
121 (119-123)
120 (118-122)
119 (117-122)
P-het 
(trend)
0.0443
(0.6362)
0.0076
(0.029)
<0.0001
(<0.0001)
<0.0001
(<0.0001)
0.3355
(0.4184)
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Abbreviations: IGF= Insulin-like growth factor; IGFBP= Insulin-like growth factor-binding protein 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3: Relative geometric mean concentrations* of IGFs and IGFBPs in males by waist-to-hip ratio 
P for heterogeneity is the heterogeneity of means between categories, tested using the F test. P for trend was calculated using the analysis of variance test, with categorical variables entered as 
linear values scored consecutively.    
*relative to < 0.900-0.932 
#significant heterogeneity by study P<0.01  
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Relative geometric mean* (95% CI)
0.5 1 1.5 2
Relative geometric mean* (95% CI)
IGF and IGFBP 
concentrations 
by waist-to-hip 
ratio
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0.933-0.966
0.967-0.999
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<0.900
0.900-0.932
0.933-0.966
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1.000+
<0.900
0.900-0.932
0.933-0.966
0.967-0.999
1.000+
IGF-I (nmol/L)
IGF-II (nmol/L)
IGFBP-1 (nmol/L)
IGFBP-2 (nmol/L)
IGFBP-3  (nmol/L)
N
1432
1430
1595
1171
1617
766
785
934
698
856
986
1018
1085
748
1004
646
672
807
620
769
1148
1170
1307
991
1358
Geometric mean 
concentration 
(95% CI) 
20.9 (20.5-21.3)
21.6 (21.2-22.0)
21.4 (21.0-21.8)
21.4 (20.9-21.8)
20.9 (20.5-21.2)
94 (92-96)
97 (95-98)
98 (96-99)
97 (95-99)
97 (95-99)
0.29 (0.28-0.31)
0.23 (0.22-0.24)
0.19 (0.18-0.20)
0.18 (0.17-0.19)
0.15 (0.14-0.16)
8.4 (8.0-8.7)
6.7 (6.5-7.0)
5.6 (5.4-5.8)
5.2 (5.0-5.5)
4.7 (4.5-4.9)
118 (116-120)
120 (118-121)
120 (119-122)
120 (118-122)
119 (118-121)
P-het 
(trend)
0.0287
(0.5154)
0.0832 #
(0.0428)
<0.0001
(<0.0001)
<0.0001
(<0.0001)
0.4394
(0.4152)
Geometric mean 
concentration (95% 
CI) further adjusted 
for BMI
20.9 (20.5-21.3)
21.4 (21.0-21.8)
21.3 (20.9-21.7)
21.3 (20.9-21.8)
21.3 (21.7-21.5)
95 (93-97)
97 (95-100)
97 (96-99)
97 (95-99)
97 (95-99)
0.23 (0.22-0.25)
0.21 (0.20-0.22)
0.20 (0.19-0.21)
0.19 (0.18-0.21)
0.19 (0.18-0.20)
6.80 (6.49-7.12)
6.19 (5.94-6.46)
5.75 (5.54-5.97)
5.60 (5.37-5.85)
5.57 (5.35-5.81)
118 (116-120)
119 (118-121)
120 (118-122)
120 (118-122)
120 (118-122)
P-het 
(trend)
0.4011
(0.7684)
0.7137 #
(0.4796)
<0.0001
(<0.0001)
<0.0001
(<0.0001)
0.7065
(0.3042)
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Abbreviations: IGF= Insulin-like growth factor; IGFBP= Insulin-like growth factor-binding protein 
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Supplementary Figure 4: Relative geometric mean concentrations* of IGFs and IGFBPs in males by marriage 
status, adjusted for study, age, height and BMI 
P for heterogeneity is the heterogeneity of means between categories, tested using the F test. There was no statistically significant 
heterogeneity by study 
*relative to currently married/cohabiting 
Abbreviations: IGF= Insulin-like growth factor; IGFBP= Insulin-like growth factor-binding protein 
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IGF and IGFBP 
concentrations 
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Married/cohabiting
Not married/cohabiting
Married/cohabiting
Not married/cohabiting
Married/cohabiting
Not married/cohabiting
Married/cohabiting
Not married/cohabiting
Married/cohabiting
Not married/cohabiting
IGF-I (nmol/L)
IGF-II (nmol/L)
IGFBP-1 (nmol/L)
IGFBP-2 (nmol/L)
IGFBP-3 (nmol/L)
N
7979
1273
3791
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4025
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2973
406
6892
1123
Geometric mean 
concentration 
(95% CI)
20.4 (20.2-20.7)
19.7 (19.2-20.1)
76 (75-78)
73 (71-75)
0.27 (0.26-0.27)
0.29 (0.27-0.31)
7.74 (7.54-7.95)
8.14 (7.68-8.62)
107 (106-108)
105 (103-107)
P-het
`0.0006
`0.0009
0.019
0.0897
0.0322
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Supplementary Figure 5: Relative geometric mean concentrations* of IGFs and IGFBPs in males by family 
history of prostate cancer, adjusted for study, age, height and BMI 
P for heterogeneity is the heterogeneity of means between categories, tested using the F test. There was no statistically significant 
heterogeneity by study 
*relative to no family history of prostate cancer 
Abbreviations: IGF= Insulin-like growth factor; IGFBP= Insulin-like growth factor-binding protein 
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by family history 
of prostate cancer
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Yes
No
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IGF-II (nmol/L)
IGFBP-1 (nmol/L)
IGFBP-2 (nmol/L)
IGFBP-3 (nmol/L)
N
6214
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404
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concentration 
(95% CI)
21.9 (21.5-22.3)
21.7 (21.1-22.4)
115 (113-117)
113 (110-117)
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0.73 (0.60-0.90)
15.1 (14.8-15.4)
15.4 (14.4-16.4)
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P-het
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 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6: Relative geometric mean concentrations of IGFBP-1 by fasting status* 
P for heterogeneity is the heterogeneity of means between categories, tested using the LR test. P for trend was calculated using the analysis of variance test, with categorical variables entered 
as linear values scored consecutively. 
* Overnight fasting status was recorded in EPIC, HIMS and MEC studies 
# Significant heterogeneity by fasting status P<0.01  
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Relative geometric mean (95% CI)
0.5 1 1.5 2
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IGFBP-1 
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of exposure
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55-59
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65-69
70-74
75+
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20.0-22.5
22.5-24.9
25-27.5
27.5-29.9
30.0-32.5
32.5-34.9
35.0-37.4
37.5+
<160
160-164
165-169
170-174
175-179
180-184
185-189
190+
never
ex
light (1-14)
med (15-29)
heavy (30+)
none
1-9
10-19
20-29
30-39
40-49
50-59
60-69
70+
Age, years #
BMI, kg/m²
Height, cm
Smoking 
Alcohol
N 
overnight 
fast
171
180
303
295
253
665
722
35
217
573
764
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285
95
33
32
95
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562
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520
308
109
24
746
1225
116
107
22
460
576
415
305
176
107
74
39
64
Geometric mean 
concentration (95% 
CI) overnight 
fast
0.25 (0.22-0.28)
0.25 (0.23-0.29)
0.29 (0.26-0.32)
0.31 (0.28-0.34)
0.34 (0.31-0.38)
0.38 (0.36-0.41)
0.48 (0.45-0.51)
0.75 (0.59-0.93)
0.62 (0.56-0.68)
0.46 (0.44-0.49)
0.36 (0.35-0.38)
0.30 (0.28-0.31)
0.27 (0.25-0.30)
0.22 (0.19-0.25)
0.15 (0.12-0.19)
0.17 (0.13-0.21)
0.44 (0.39-0.51)
0.44 (0.40-0.48)
0.38 (0.36-0.41)
0.35 (0.33-0.37)
0.35 (0.33-0.37)
0.32 (0.29-0.34)
0.30 (0.27-0.34)
0.28 (0.21-0.37)
0.34 (0.32-0.35)
0.32 (0.31-0.33)
0.34 (0.30-0.38)
0.38 (0.34-0.44)
0.58 (0.44-0.77)
0.34 (0.32-0.37)
0.33 (0.31-0.35)
0.33 (0.31-0.35)
0.33 (0.31-0.36)
0.30 (0.27-0.33)
0.34 (0.30-0.38)
0.36 (0.31-0.42)
0.34 (0.28-0.42)
0.33 (0.28-0.39)
P-het 
(trend) 
<0.0001
(<0.0001)
<0.0001
(<0.0001)
<0.0001
(<0.0001)
<0.0001
(0.0001)
0.6578
(0.8260)
N no 
overnight 
fast
141
177
197
173
58
115
180
11
83
249
345
220
87
33
15
5
18
89
191
281
255
156
44
12
323
493
60
81
28
166
280
200
131
69
57
21
35
26
Geometric mean 
concentration (95% 
CI) no overnight 
fast
0.07 (0.06-0.08)
0.07 (0.06-0.08)
0.07 (0.07-0.08)
0.08 (0.07-0.09)
0.09 (0.08-0.12)
0.10 (0.08-0.12)
0.12 (0.09-0.15)
Insufficient data
0.14 (0.11-0.16)
0.10 (0.09-0.11)
0.09 (0.08-0.10)
0.07 (0.06-0.07)
0.06 (0.06-0.07)
0.07 (0.05-0.09)
Insufficient data
Insufficient data
Insufficient data
0.11 (0.09-0.12)
0.09 (0.08-0.10)
0.09 (0.08-0.10)
0.08 (0.07-0.08)
0.08 (0.07-0.09)
0.07 (0.06-0.09)
Insufficient data
0.08 (0.08-0.09)
0.08 (0.07-0.09)
0.09 (0.08-0.11)
0.10 (0.08-0.12)
0.10 (0.07-0.13)
0.09 (0.08-0.10)
0.08 (0.08-0.09)
0.08 (0.07-0.09)
0.09 (0.07-0.10)
0.08 (0.07-0.10)
0.07 (0.06-0.09)
0.06 (0.05-0.09)
0.09 (0.07-0.11)
0.09 (0.06-0.12)
P-het 
(trend)
0.0095
(0.0002)
<0.0001
(<0.0001)
0.0023
(0.0001)
0.1243
(0.0163)
0.5663
(0.8969)
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Abbreviations: BMI= Body mass index; EPIC= European Prospective Investigation into Cancer and Nutrition; HIMS= Health In Men Study; IGFBP= Insulin-like growth factor-binding 
protein; MEC= Multiethnic Cohort Study of Diet and Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7: Relative geometric mean concentrations of IGFBP-2 by fasting status* 
P for heterogeneity is the heterogeneity of means between categories, tested using the LR test. P for trend was calculated using the analysis of variance test, with categorical variables entered 
as linear values scored consecutively.    
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Geometric mean 
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fast
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5.48 (4.74-6.32)
3.63 (3.35-3.94)
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2.49 (2.28-2.72)
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1.97 (1.58-2.46)
Insufficient data
3.65 (3.13-4.26)
2.80 (2.53-3.10)
3.03 (2.81-3.26)
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2.84 (2.58-3.13)
2.57 (2.14-3.08)
2.91 (2.71-3.13)
2.83 (2.66-3.01)
3.08 (2.67-3.56)
3.61 (3.19-4.10)
3.09 (2.73-3.49)
3.05 (2.84-3.28)
2.79 (2.56-3.05)
2.99 (2.67-3.34)
2.99 (2.58-3.47)
2.89 (2.44-3.41)
Insufficient data
3.15 (2.55-3.89)
2.80 (2.23-3.51)
5.11 (4.24-6.15)
Insufficient data
Insufficient data
Insufficient data
Insufficient data
Insufficient data
2.94 (2.37-3.64)
P-het 
(trend)
<0.0001
(<0.0001)
(<0.0001)
0.0343
(0.2035)
0.0166
(0.0094)
0.4820
(0.3594)
<0.0001
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* Overnight fasting status was recorded in EPIC. 
# Significant heterogeneity by fasting status P<0.01  
Abbreviations: BMI= Body mass index; EPIC= European Prospective Investigation into Cancer and Nutrition; IGFBP= Insulin-like growth factor-binding protein
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